Moleculin Biotech, Inc.
MBRX
$0.9502
$0.07538.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 81.67% | -88.84% | 27.73% | 37.21% | -51.68% |
| Total Depreciation and Amortization | -11.43% | 3.23% | 0.00% | 6.67% | 9.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -301.51% | 694.93% | -363.91% | -163.64% | 458.68% |
| Change in Net Operating Assets | -67.45% | 121.41% | -220.11% | -275.86% | 457.91% |
| Cash from Operations | -3.80% | 19.04% | -16.06% | -11.63% | 32.51% |
| Capital Expenditure | 100.00% | 100.00% | 13.33% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | 100.00% | 13.33% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.97% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | 75.00% | -19.05% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.97% | 116,575.00% | -151.02% | -- | -- |
| Foreign Exchange rate Adjustments | -650.00% | 240.00% | 900.00% | -125.00% | -166.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -398.25% | 81.04% | -17.40% | -14.39% | 85.80% |